A study with the diabetes vaccine Diamyd in type 1 diabetes patients.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 16 Aug 2017 New trial record
- 10 Aug 2017 According to a Diamyd Medical AB media release, Chief Investigator is Professor Colin Dayan and Principal Investigator is Dr. Danijela Tatovic.